跳至主要内容
临床试验/NCT07547787
NCT07547787招募中不适用

An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Akeso1 个研究点 分布在 1 个国家目标入组 610 人开始时间: 2024年12月26日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
610
试验地点
1
主要终点
Overall Survival (OS)

研究概览

简要总结

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
  • Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
  • Agree to proceed with the extended follow-up procedures.
  • This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.

排除标准

  • 未提供

结局指标

主要结局

Overall Survival (OS)

时间窗: Up to approximately 5 years

OS is defined as the time from randomization to death due to any cause.

次要结局

未报告次要终点

研究者

发起方
Akeso
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验